156 related articles for article (PubMed ID: 38251522)
1. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.
Singla S; Putman M; Liew J; Gordon K
Lancet Rheumatol; 2023 Apr; 5(4):e200-e207. PubMed ID: 38251522
[TBL] [Abstract][Full Text] [Related]
2. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
[TBL] [Abstract][Full Text] [Related]
3. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
Pina Vegas L; Penso L; Claudepierre P; Sbidian E
JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
[TBL] [Abstract][Full Text] [Related]
4. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities.
Koehm M; Behrens F
RMD Open; 2023 Sep; 9(3):. PubMed ID: 37734874
[TBL] [Abstract][Full Text] [Related]
5. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis.
Eder L; Mylvaganam S; Pardo Pardo J; Petkovic J; Strand V; Mease P; Colaco K
Lancet Rheumatol; 2023 Dec; 5(12):e716-e727. PubMed ID: 38251562
[TBL] [Abstract][Full Text] [Related]
6. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
Al-Janabi A; Alabas OA; Yiu ZZN; Foulkes AC; Eyre S; Khan AR; Reynolds NJ; Smith CH; Griffiths CEM; Warren RB;
JAMA Dermatol; 2024 Jan; 160(1):71-79. PubMed ID: 38055239
[TBL] [Abstract][Full Text] [Related]
7. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
8. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
[TBL] [Abstract][Full Text] [Related]
9. Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis.
Jin Y; Chen SK; Lee H; Landon JE; Merola JF; Kim SC
J Manag Care Spec Pharm; 2021 Aug; 27(8):1106-1117. PubMed ID: 34337987
[No Abstract] [Full Text] [Related]
10. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
11. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Emond B; Ellis LA; Chakravarty SD; Ladouceur M; Lefebvre P
Curr Med Res Opin; 2019 Oct; 35(10):1751-1759. PubMed ID: 31106607
[No Abstract] [Full Text] [Related]
12. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
[TBL] [Abstract][Full Text] [Related]
13. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
Xie Y; Liu Y
Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
[TBL] [Abstract][Full Text] [Related]
14. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
[TBL] [Abstract][Full Text] [Related]
15. Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases.
Bhattacharya R; Herren K; Poonawalla I; Bunniran S; Bloomfield A; Schwab P
J Manag Care Spec Pharm; 2020 Oct; 26(10):1246-1256. PubMed ID: 32996385
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
Waljee AK; Higgins PDR; Jensen CB; Villumsen M; Cohen-Mekelburg SA; Wallace BI; Berinstein JA; Allin KH; Jess T
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):276-284. PubMed ID: 31836320
[TBL] [Abstract][Full Text] [Related]
17. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis.
Gisondi P; Bellinato F; Targher G; Idolazzi L; Girolomoni G
Ann Rheum Dis; 2022 Jan; 81(1):68-73. PubMed ID: 34144965
[TBL] [Abstract][Full Text] [Related]
18. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
19. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
Penso L; Dray-Spira R; Weill A; Pina Vegas L; Zureik M; Sbidian E
JAMA Dermatol; 2021 Sep; 157(9):1056-1065. PubMed ID: 34287624
[TBL] [Abstract][Full Text] [Related]
20. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
